Three methods for estimating free thyroxine (FT,) in serum were studied: equilibrium dialysis, the SPAC-ET FT4 radioimmunoassay kit, and the Amerlite to the previously supplied Amerlex-M Fr4 kit, which used an analog of T4 as tracer. This analog was designed to bind to the antiserum used in the Fr4 RIA, but not to serum binding proteins present in the incubation mixtures. However, it appeared that, especially in the case of large changes in albumin concentrations, or in the presence of fimi1ia1 dysalbuminemic hyperthyroxinemia (FDH) (7; for a review, see 8), binding to albumin did occur, leading to falselyincreased values for Fr4 (9). Also the Amerlite Fr4 kit, which was introduced thereafter and uses a horseradish peroxidase (EC 1.11.1.7)-conjugated T4 instead of an analog, appeared not to be completely free of these artifacts caused by FDH albumin (10). However, this new Amerlite MAB FT4 kit is still an analog method, using T3 coupled to the wall of the incubation wells as the analog. Any
intensive-care unit, whereas by commercially available Fr4 kits, between 30% and 100% of these samples were subnormal, depending on the kit used. Similarly, Wang et al. (3), using ultrafiltration and RIA methods, reported decreased Fr4 values in critically ifi patients. However, Surks et al. (4) showed with both ultrafiltration and equilibrium dialysisof undiluted serum that F4 was normal in all 30 intensive-care patients studied. Finally, we have shown that Fr4 by equilibrium dialysis was above normal in 54% of a group of 504 patients with mild to severe NT! (1), although this percentage was much lower (24%) in the most severely ifi group. Therefore, the differences in the reported FT,1 concentrations in NT! patients may be attributed to the description accompanying the kit-should be free from the discrepancies seen with analog tracer assays, similar to the previously supplied Amerlex-M Fr4 kit, which used an analog of T4 as tracer. This analog was designed to bind to the antiserum used in the Fr4 RIA, but not to serum binding proteins present in the incubation mixtures. However, it appeared that, especially in the case of large changes in albumin concentrations, or in the presence of fimi1ia1 dysalbuminemic hyperthyroxinemia (FDH) (7; for a review, see 8) , binding to albumin did occur, leading to falselyincreased values for Fr4 (9) . Also the Amerlite Fr4 kit, which was introduced thereafter and uses a horseradish peroxidase (EC 1.11.1.7)-conjugated T4 instead of an analog, appeared not to be completely free of these artifacts caused by FDH albumin (10). However, this new Amerlite MAB FT4 kit is still an analog method, using T3 coupled to the wall of the incubation wells as the analog. Any serum constituent that binds to this solid-phase analog will interfere with the binding of the labeled antibody to the wall of the wells. All estimations were performed in duplicate.
Samples
Serum pools with low, medium, and high total or free thyroid hormone concentrations (different sets for each assay) were constructed by mixing patients' sera sent to the routine laboratory for assessment of thyroid hormone parameters. Sera were allotted to the different pools on the basis of the results of these measurements.
Sera from 42 normal blood donors (12 men, 30 women) served as controls. Sera from 29 FDH subjects (members of seven different families), 10 subjects (4 men and 6 women taking oral contraceptives) with above-normal serum TBG, and 6 subjects with low or absent serum TBG were investigated. We also assayed 13 sera from euthyroid hyperlipemic subjectswith nonesterifled fatty acids (NEFA) >1.0 mmol/L and normal concentrations of serum TSH.
We investigated 178 sera from NT! patients, newly Table 1 shows the reproducibility of the assays used in this study. Three different serum pools (with low, medium, and high total and free thyroid hormone concentrations, one set for each assay) were measured in 10 consecutive assays on different days. The low coefficients of variation (CVs) indicate that the run-to-run stability was good. Table 2 shows the mean total thyroid hormone concentrations and the mean results of the three Fr4 assays in the sera from 42 controls, used in this study, and the reference values for the different assays, as estimated in a much larger group (n = 200) of blood donors. Figure 1 shows the relation between the Amerlite MAB Fr4 and the equilibrium dialysis results for the 42 control subjects. The correlation between both assays is good (r = 0.92), with a slope near unity.
Results
Changes in TBG binding did not significantly NT! subjects, respectively) show the actual mean values. Mean Fr4 in moderately ill patients (groups I! and I!!) is significantly higher than in control subjects, the highestnumber of increased values being seen in group ifi as estimated by the Amerlite MAB Fr4 assay (25 of 57; Table 5 ). This effect is even more pronounced with the equilibrium dialysis method, and to a lesser extent is present in the data from the SPAC-ET assay. The mean Fr4 value in the severely ill patients (group IV) is still significantly different from the controls (Table 4 ), but this difference is much less than for groups II and Ill-reflected by a smaller number of FT4 values in group IV that are outside the reference range. Table 5 summarizes the number of FT4 values obtained with the different assays in the NT! samples outside the estimated reference interval. Figure   4 shows the relation between the Amerlite MAB Fr4 and the equilibrium dialysis results for all samples tested in this study.
Finally,
we calculated the correlations (orthogonal Significantlydifferent from the mean of the control groupestimated with the same assay: a P <0.05; b P <0,025; P <0.01; d p <0.001. 
MAB
Fr4 assay, the equilibrium dialysis method, and the SPAC-ET assay, as tested within the various groups ( Table 6 ). The correlation coefficients clearly show that FDH samples and samples from group N patients give the most discordant values between the different assays. 
Discussion
The data presented in Table 1 indicate that the reproducibility of the different assays is adequate. Most of the CVs were around 7% (range 1.9-9.6%). Of the Fr4 assays tested, the FT4 Amerlite MAB had the lowest CVs and the Fr4 SPAC-ET the highest, although the differences are only marginal.
Sera from 42 control subjects were used to establish a normal reference range for the different Fr4 assays tested here. Although measurement of 42 control sara is not enough to establish a reference range (17) , the values found were not significantly different from our laboratory reference values estimated in a group of 200 blood donors (Table 2) . Therefore, we think the use of this small control group in this study is justified, because it appears to be a representative sample of the with our in-house dialysis technique, and the resulting value is used instead of the one proposed by BykSangtec, the values obtained are similar to those by equilibrium dialysis. Neither increases nor deficiencies of serum TBG concentrationsignificantly affected the final FT4 concentration in the three assays tested (Table 3) is able to traverse the dialysismembrane, the above discussion applies; however, if the inhibitor is not able to traverse the membrane, then only the dilution of the serum inside the dialysis bag has to be taken into account, which is only one-fifth of the total dilution of the system. This could be an explanation for the data presented in Figure 2 , from which we condude that only the results obtained by equilibrium dialysis show a dependence of Fr4 on dilution. The large standard deviation of the data points indicates that in some NTI sara the effect of dilution is considerable, whereas others exhibit no effect at all. In general, therefore, assessment of Fr4 in NT! should be performed with minimal sample dilution, to rule out any effect caused by dilution and to reflect the in vivo situation as closely as possible. Another explanation for the fact that the results of the SPAC-ET FT4 and the Amerlite MAR Fr4 assays are only minimally affected by dilution could be that, in both assays, the putative inhibitor of the serum T4-binding inhibits to a similrn extent T4 binding to the T4 antibodies used in these assays.
It is generally accepted that evaluation of thyroid function in patients with nonthyroidal illness is difficult. Such patients develop a so-called low-T3 syndrome with increased rT3 concentrations (because of the decreased metabolic clearance of rT3), lower than normal T3 concentrations (caused by decreased peripheral production ofT3 from T4) and, in cases of critical illnesses, also depressed total T4 concentrations (attributable to decreased production and serum binding of T4) (27 N (1, 28,29) . Regression analysis within the various groups (Table  6 ) yielded a rather poor correlation between the Fr4 values obtained by the three assays, especially in the FDH subjects and the NT! group N patients. Perhaps the variations are caused by changes in albumin-T4 binding, as seen in FDH, where it is increased, and in NT!, where albumin concentrations are almost invariably depressed in moderately and severely ill patients (28, 29) . At first, this seems a part of the explanation in the case of the Amerlite MAB FT4 assay, because with this assay we found that the mean Fr4 value in the FDH group was lower, and the mean Fr4 value in the NT! group was higher than in the control group. However, it is equally possiblethat there is no common denominator for the observed deviations of the mean FT4 from the control mean in the FDH and NTI groups, because the three assays all produced significantly increased mean Fr4 values in the NT! groups I!, I!!, and N (Table 4) , whereas the change in the mean FT4 in the FDH group was assay dependent (Table 3 ).
The SPAC-ET Fr4 assay, as well as the Fr4 estimated by equilibrium dialysis, is dependent on the total T4 assay, because in fact both assays measure a free (i.e., unbound) fraction, which has to be multiplied by the total T4 in serum to obtain the actual Fr4 value. Therefore instead of one, two measurements have to be performed to obtain the serum Fr4 concentration, which obviously increases the workload of the laboratory.
The Amerlite MAR Fr4 assay, on the other hand, is easy and rapid to perform and produces Fr4 results that are not dependent on the estimation of the total T4 concentration.
Finally, it appears that the absolute free hormone Aeferences
